CHANGES IN THE MGMT GENE EXPRESSION IN PATIENTS WITH PRIMARY GLIOBLASTOMA AFTER RELAPSE. INFLUENCE OF CLINICAL CHARACTERISTICS AND MGMT EXPRESSION ON SURVIVAL OF PATIENTS

 Background. Over the past 10–15 years, there has been a clearer understanding of the processes occurring in cells of the primary glioblastoma. However, the change in MGMT gene expression and its role after disease relapse remain understudied.

Purpose: to study changes in MGMT gene expression in case of recurrent primary glioblastoma after the standard therapy; to determine influence of  clinical factors and MGMt gene expression on relapse-free survival of patients.

Materials and Methods. We carried out a prospective analysis of clinical and molecular genetic characteristics of 21 patients aged from 28 to 63 with primary glioblastoma before and after recurrence. Relative mRna expression of MGMT gene and mutations in IDH1/IDH2 genes were determined in surgical biopsies using PCR techniques. after the first surgery, all patients received radiation therapy (60 Gy) and chemotherapy with adjuvant temozolomide (2–18 cycles). the second-line chemotherapy was performed in 17 (80.9 %) patients, and 8 patients received (47 %, 8/17) temozolomide.

Results. the relationship between the progression-free survival (PFs) and mRna expression of MGMT gene (73.5 vs 33 weeks, p=0.013) and objective response to therapy (88 vs 36 weeks, p=0.046) was found. The number of cycles of first-line chemotherapy with temozolomide influenced the duration of the first PFs (65 weeks vs 21.5 weeks, p=0,07). the first PFs was not affected by patients’ age (p=0.64), sex (p=0.17), Karnofsky performance scale index (p=0.43), extent of brain damage (p=0.41) and extent of the resection (p=0.27). after onset of relapse, mRna expression of MGMT gene remained  the same, being 66.7 % (14/21). The increased expression was observed in 23.8 % (5/21) of cases, and decreased gene expression was observed in 9.5 % (2/21) of cases. the second PFs was affected by the extent of tumor resection, although there were no statistically significant differences (p=0.52). the effect of mRna expression of MGMT gene on the median second PFs was not revealed (p=0.39). no objective response to therapy was found in patients with a low mRna expression of MGMT gene.

Conclusion. Recurrent glioblastoma becomes more resistant to further therapy. With the development of tumor recurrence, the predictive value of MGMT gene is lost and the role of the extent of cytoreductive surgery increases. 

1. Ostrom Q.T., Gittleman H., Truitt G., Boscia A., Kruchko C., Barnholtz-Sloan J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011–2015. Neuro Oncol. 2018 Oct 1; 20(suppl_4): iv1–iv86. doi: 10.1093/neuonc/noy131.

2. Noroxe D.S., Poulsen H.S., Lassen U. Hallmarks of glioblastoma: a systematic review. ESMO Open. 2017 Feb 22; 1(6): e000144. doi: 10.1136/esmoopen-2016-000144.

3. Gilbert M.R., Dignam J.J., Armstrong T.S., Wefel J.S., Blumenthal D.T., Vogelbaum M.A., Colman H., Chakravarti A., Pugh S., Won M., Jeraj R., Brown P.D., Jaeckle K.A., Schiff D., Stieber V.W., Brachman D.G., WernerWasik M., Tremont-Lukats I.W., Sulman E.P., Aldape K.D., Curran W.J.Jr., Mehta M.P. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370(8): 699–708. doi: 10.1056/NEJMoa1308573.

4. Amelot A., De Cremoux P., Quillien V., Polivka M., Adle-Biassette H., Lehmann-Che J., Françoise L., Carpentier A.F., George B., Mandonnet E., Froelich S. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. PLoS One. 2015 Jul 9; 10(7): e0130596. doi: 10.1371/journal.pone.0130596.

5. Matsko M.V., Matsko D.E., Volkov N.M., Ulitin A.Yu., Moiseenko V.M., Imyanitov E.N., Iyevleva A.G. Morphologic and molecular features of primary glioblastoma in patients surviving more than 3 years. Siberian Journal of Oncology. 2019; 18(3): 34–44. (in Russian). doi: 10.21294/1814-4861-2019-18-3-34-44.

6. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., Ludwin S.K., Allgeier A., Fisher B., Belanger K., Hau P., Brandes A.A., Gijtenbeek J., Marosi C., Vecht C.J., Mokhtari K., Wesseling P., Villa S., Eisenhauer E., Gorlia T., Weller M., Lacombe D., Cairncross J.G., Mirimanoff R.O.; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May; 10(5): 459–66. doi: 10.1016/S1470-2045(09)70025-7.

7. Zagzag D., Esencay M., Mendez O., Yee H., Smirnova I., Huang Y., Chiriboga L., Lukyanov E., Liu M., Newcomb E.W. Hypoxia- and vascular endothelial growth factor-induced stromal cell-derived factor-1alpha/CXCR4 expression in glioblastomas: one plausible explanation of Scherer’s structures. Am J Pathol. 2008 Aug; 173(2): 545–60. doi: 10.2353/ajpath.2008.071197.

8. Hegi M.E., Diserens A.C., Gorlia T., Hamou M.F., de Tribolet N., Weller M., Kros J.M., Hainfellner J.A., Mason W., Mariani L., Bromberg J.E., Hau P., Mirimanoff R.O., Cairncross J.G., Janzer R.C., Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10; 352(10): 997–1003. doi: 10.1056/NEJMoa043331.

9. Perry J.R., Laperriere N., O'Callaghan C.J., Brandes A.A., Menten J., Phillips C., Fay M., Nishikawa R., Cairncross J.G., Roa W., Osoba D., Rossiter J.P., Sahgal A., Hirte H., Laigle-Donadey F., Franceschi E., Chinot O., Golfinopoulos V., Fariselli L., Wick A., Feuvret L., Back M., Tills M., Winch C., Baumert B.G., Wick W., Ding K., Mason W.P.; Trial Investigators. Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017; 376(11): 1027–1037. doi: 10.1056/NEJMoa1611977.

10. Matsko M.V., Imaynitov E.N. Predictive role of O6-methylguanine DNA methyltransferase status for the treatment of brain tumors. Epigen Terr Cancer. 2015. 251–279. doi: 10.1007/978-94-017-9639-2_9.

11. Louis D.N., Perry A., Reifenberger G., von Deimling A., FigarellaBranger D., Cavenee W.K., Ohgaki H., Wiestler O.D., Kleihues P., Ellison D.W. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun; 131(6): 803–20. doi: 10.1007/s00401-016-1545-1.

12. Samson L., Cairns J.A new pathway for DNA repair in Escherichia coli. Nature. 1977; 267: 281–283.

13. Park C.K., Lee S.H., Kim T.M., Choi S.H., Park S.H., Heo D.S., Kim I.H., Jung H.W. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. J Neurooncol. 2013 Apr; 112(2): 277–83. doi: 10.1007/s11060-013-1060-3.

14. Chen C., Xu T., Lu Y., Chen J., Wu S. The efficacy of temozolomide for recurrent glioblastoma multiforme. Eur J Neurol. 2013 Feb; 20(2): 223–30. doi: 10.1111/j.1468-1331.2012.03778.x.

15. Campos B., Olsen L.R., Urup T., Poulsen H.S. A comprehensive profile of recurrent glioblastoma. Oncogene. 2016 Nov 10; 35(45): 5819–5825. doi: 10.1038/onc.2016.85.

16. Kim J., Lee I.H., Cho H.J., Park C.K., Jung Y.S., Kim Y., Nam S.H., Kim B.S., Johnson M.D., Kong D.S., Seol H.J., Lee J.I., Joo K.M., Yoon Y., Park W.Y., Lee J., Park P.J., Nam D.H. Spatiotemporal Evolution of the Primary Glioblastoma Genome. Cancer Cell. 2015 Sep 14; 28(3): 318–28. doi: 10.1016/j.ccell.2015.07.013.

17. Kim H., Zheng S., Amini S.S., Virk S.M., Mikkelsen T., Brat D.J., Grimsby J., Sougnez C., Muller F., Hu J., Sloan A.E., Cohen M.L., Van Meir E.G., Scarpace L., Laird P.W., Weinstein J.N., Lander E.S., Gabriel S., Getz G, Meyerson M., Chin L., Barnholtz-Sloan J.S., Verhaak R.G. Whole-genome and multisector exome sequencing of primary and posttreatment glioblastoma reveals patterns of tumor evolution. Genome Res. 2015 Mar; 25(3): 316–27. doi: 10.1101/gr.180612.114.

18. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Central Nervous System Cancers. Version 2.2019.

19. Mitiushkina N.V., Iyevleva A.G., Poltoratskiy A.N., Ivantsov A.O., Togo A.V., Polyakov I.S., Orlov S.V., Matsko D.E., Novik V.I., Imyanitov E.N. Detection of EGFR mutations and EML4-ALK rearrangements in lung adenocarcinomas using archived cytological slides. Cancer Cytopathol. 2013 Jul; 121(7): 370–6. doi: 10.1002/cncy.21281.

20. Wen P.Y., Macdonald D.R, Reardon D.A., Cloughesy T.F., Sorensen A.G., Galanis E., Degroot J., Wick W., Gilbert M.R., Lassman A.B., Tsien C., Mikkelsen T., Wong E.T., Chamberlain M.C., Stupp R., Lamborn K.R., Vogelbaum M.A., van den Bent M.J., Chang S.M. Updated response assessment criteria for high-grade gliomas: response assessment in neurooncology working group. J Clin Oncol. 2010 Apr 10; 28(11): 1963–72. doi: 10.1200/JCO.2009.26.3541.

21. Zhang C., Yao Y., Wang Y., Chen Z., Wu J., Mao Y., Zhou L. Temozolomide for adult brain stem glioblastoma: case report of a long-term survivor. Int J Neurosci. 2010 Dec; 120(12): 787–91. doi: 10.3109/00207454.2010.520377.

22. Marchi F., Sahnane N., Cerutti R., Cipriani D., Barizzi J., Stefanini F.M., Pistolio S., Cerati M., Balbi S., Mazzucchelli L., Sessa F., Pesce G.A., Reinert M., Frattini M. The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation. Front Oncol. 2020 Jan 24; 9: 1569. doi: 10.3389/fonc.2019.01569.

23. Felsberg J., Rapp M., Loeser S., Fimmers R., Stummer W., Goeppert M., Steiger H.J., Friedensdorf B., Reifenberger G., Sabel M.C. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009 Nov 1; 15(21): 6683–93. doi: 10.1158/1078-0432.CCR-08-2801.

24. Quillien V., Lavenu A., Sanson M., Legrain M., Dubus P., KarayanTapon L., Mosser J., Ichimura K., Figarella-Branger D. Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients. J Neurooncol. 2014 Feb; 116(3): 487–96. doi: 10.1007/s11060-013-1332-y.

25. Parkinson J.F., Wheeler H.R., Clarkson A., McKenzie C.A., Biggs M.T., Little N.S., Cook R.J., Messina M., Robinson B.G., McDonald K.L. Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma. J Neurooncol. 2008 Mar; 87(1): 71–8. doi: 10.1007/s11060-007-9486-0.

26. Metellus P., Coulibaly B., Nanni I., Fina F., Eudes N., Giorgi R., Barrie M., Chinot O., Fuentes S., Dufour H., Ouafik L., Figarella-Branger D. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. Cancer. 2009 Oct 15; 115(20): 4783–94. doi: 10.1002/cncr.24546.

27. Christmann M., Nagel G., Horn S., Krahn U., Wiewrodt D., Sommer C., Kaina B. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int J Cancer. 2010 Nov 1; 127(9): 2106–18. doi: 10.1002/ijc.25229.

28. Jung T.Y., Jung S., Moon K.S., Kim I.Y., Kang S.S., Kim Y.H., Park C.S., Lee K.H. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol Rep. 2010; 23(5): 1269–76. doi: 10.3892/or_00000760.

29. Felsberg J., Thon N., Eigenbrod S., Hentschel B., Sabel M.C., Westphal M., Schackert G., Kreth F.W., Pietsch T., Löffler M., Weller M., Reifenberger G., Tonn J.C.; German Glioma Network. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 2011 Aug 1; 129(3): 659–70. doi: 10.1002/ijc.26083.

30. Felsberg J., Thon N., Eigenbrod S., Hentschel B., Sabel M.C., Westphal M., Schackert G., Kreth F.W., Pietsch T., Löffler M., Weller M., Reifenberger G., Tonn J.C.; German Glioma Network. Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. Int J Cancer. 2011 Aug 1; 129(3): 659–70. doi: 10.1002/ijc.26083.

31. Brandes A.A., Franceschi E., Tosoni A., Bartolini S., Bacci A., Agati R., Ghimenton C., Turazzi S., Talacchi A., Skrap M., Marucci G., Volpin L., Morandi L., Pizzolitto S., Gardiman M., Andreoli A., Calbucci F., Ermani M. O(6)-methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol. 2010 Mar; 12(3): 283–8. doi: 10.1093/neuonc/nop050.

32. Brandes A.A., Franceschi E., Paccapelo A., Tallini G., De Biase D., Ghimenton C., Danieli D., Zunarelli E., Lanza G., Silini E.M., Sturiale C., Volpin L., Servadei F., Talacchi A., Fioravanti A, Pia Foschini M., Bartolini S., Pession A., Ermani M. Role of MGMT Methylation Status at Time of Diagnosis and Recurrence for Patients with Glioblastoma: Clinical Implications. Oncologist. 2017 Apr; 22(4): 432–437. doi: 10.1634/theoncologist.2016-0254.

33. O'Regan C.J., Kearney H., Beausang A., Farrell M.A., Brett F.M., Cryan J.B., Loftus T.E., Buckley P.G. Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol. J Neurooncol. 2018 Apr; 137(2): 233–240. doi: 10.1007/s11060-017-2722-3.

34. Hudson A.L., Parker N.R., Khong P., Parkinson J.F., Dwight T., Ikin R.J., Zhu Y., Chen J., Wheeler H.R., Howell V.M. Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment. Front Oncol. 2018; 8: 314. doi: 10.3389/fonc.2018.00314.

35. Gutenberg A., Bock H.C., Brück W., Doerner L., Mehdorn H.M., Roggendorf W., Westphal M., Felsberg J., Reifenberger G., Giese A. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers. Br J Neurosurg. 2013 Dec; 27(6): 772–8. doi: 10.3109/02688697.2013.791664.

36. Weller M., Tabatabai G., Kästner B., Felsberg J., Steinbach J.P., Wick A., Schnell O., Hau P., Herrlinger U., Sabel M.C., Wirsching H.G., Ketter R., Bähr O., Platten M., Tonn J.C., Schlegel U., Marosi C., Goldbrunner R., Stupp R., Homicsko K., Pichler J., Nikkhah G., Meixensberger J., Vajkoczy P., Kollias S., Hüsing J., Reifenberger G., Wick W.; DIRECTOR Study Group. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose- Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clin Cancer Res. 2015 May 1; 21(9): 2057–64. doi: 10.1158/1078-0432.CCR-14-2737.

37. Sadones J., Michotte A., Veld P., Chaskis C., Sciot R., Menten J., Joossens E.J., Strauven T., D'Hondt L.A., Sartenaer D., Califice S.F., Bierau K., Svensson C., De Grève J., Neyns B. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma. Eur J Cancer. 2009 Jan; 45(1): 146–53. doi: 10.1016/j.ejca.2008.09.002.

38. Quick J., Gessler F., Dützmann S., Hattingen E., Harter P.N., Weise L.M., Franz K., Seifert V., Senft C. Benefit of tumor resection for recurrent glioblastoma. J Neurooncol. 2014 Apr; 117(2): 365–72. doi: 10.1007/s11060-014-1397-2.